4.8 Article

YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology

期刊

NATURE COMMUNICATIONS
卷 11, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-020-14353-6

关键词

-

资金

  1. Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) from the Japan Agency for Medical Research and Development (AMED) [JP18dm0207013h0005]
  2. Strategic Research Program for Brain Sciences (SRPBS) [JP18dm0107057h0002, JP17dm0107057h0002]
  3. Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22110001, 22110002]
  4. AMED [JP18dm0107103]
  5. NIH [PO1AG14449]
  6. Grants-in-Aid for Scientific Research [22110002, 22110001] Funding Source: KAKEN

向作者/读者索取更多资源

The timing and characteristics of neuronal death in Alzheimer's disease (AD) remain largely unknown. Here we examine AD mouse models with an original marker, myristoylated alanine-rich C-kinase substrate phosphorylated at serine 46 (pSer46-MARCKS), and reveal an increase of neuronal necrosis during pre-symptomatic phase and a subsequent decrease during symptomatic phase. Postmortem brains of mild cognitive impairment (MCI) rather than symptomatic AD patients reveal a remarkable increase of necrosis. In vivo imaging reveals instability of endoplasmic reticulum (ER) in mouse AD models and genome-edited human AD iPS cell-derived neurons. The level of nuclear Yes-associated protein (YAP) is remarkably decreased in such neurons under AD pathology due to the sequestration into cytoplasmic amyloid beta (A beta) aggregates, supporting the feature of YAP-dependent necrosis. Suppression of early-stage neuronal death by AAV-YAPdeltaC reduces the later-stage extracellular A beta burden and cognitive impairment, suggesting that preclinical/prodromal YAP-dependent neuronal necrosis represents a target for AD therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据